


This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1(original). Compounds of formula (I)



in which:

R<sup>1</sup> and R<sup>2</sup>, which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group;

R<sup>3</sup> represents a methyl group having α- or β-configuration;

R<sup>4</sup> represents a hydrogen atom or an etherifying or esterifying group;

R<sup>5</sup> represents a hydrogen atom, a hydroxyl group or a lower alkoxy group;

X represents a group OR<sup>4</sup>, wherein R<sup>4</sup> is as defined above, or a group NR<sup>6</sup>R<sup>7</sup> wherein R<sup>6</sup> represents a hydrogen atom, an aliphatic or araliphatic organic group, or an acyl group comprising an aliphatic, araliphatic or aryl organic group linked to the nitrogen atom by way of a carbonyl group; and R<sup>7</sup> is a hydrogen atom or a lower alkyl group;

Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and

~~the dotted lines signify that double bonds may be present at the 16(17)-position and/or either at the 6(7)- and 8(9)-positions or at the 7(8)-position.~~

*Sub  
C2  
cont.*  
~~2(original). Compounds of formula (I) as claimed in claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from C<sub>1-6</sub> alkyl groups and C<sub>2-7</sub> alkenyl and alkynyl groups.~~

~~3(original). Compounds of formula (I) as claimed in claim 2 wherein R<sup>1</sup> and R<sup>2</sup> are straight chain groups.~~

~~4(original). Compounds of formula (I) as claimed in claim 2 wherein R<sup>1</sup> and R<sup>2</sup> are selected from methyl, ethyl and propargyl groups.~~

*B)*  
~~5(previously presented). Compounds of formula (I) as claimed in claim 1 wherein R<sup>4</sup> a hydrogen atom, a silyl group, a C<sub>1-6</sub> alkyl group optionally interrupted by one or more oxygen atoms or substituted by a lower cycloalkyl group, a cyclic ether group, a C<sub>1-6</sub> alkanoyl group, an aroyl group, a C<sub>1-6</sub> alkane sulphonyl or halogenated methane sulphonyl group, or an arene sulphonyl group.~~

~~6(original). Compounds of formula (I) as claimed in claim 5 wherein R<sup>4</sup> is a hydrogen atom.~~

~~7(original). Compounds of formula (I) as claimed in claim 5 wherein R<sup>4</sup> is a metabolically labile group or a lower alkyl group.~~

~~8(previously presented). Compounds of formula (I) as claimed in claim 1 wherein R<sup>5</sup> represents a hydrogen atom or a methoxy group.~~

~~9(previously presented). Compounds of formula (I) as claimed in claim 1 wherein X represents a hydroxyl group or a group of formula NR<sup>6</sup>R<sup>7</sup> wherein:~~

Appl. No. 09/926,491  
Amendment dated: August 7, 2003  
Reply to OA of: April 7, 2003

~~R<sup>6</sup> is a C<sub>1-6</sub> alkyl group, C<sub>6-12</sub> carbocyclic aryl C<sub>1-4</sub> alkyl group, C<sub>1-6</sub> alkanoyl group, C<sub>6-12</sub> carbocyclic aryl C<sub>2-5</sub> alkanoyl group, C<sub>7-13</sub> carbocyclic aroyl group or any of the preceding groups substituted by one or more halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkanoyl, C<sub>1-4</sub> alkylamino, di (C<sub>1-4</sub> alkyl) amino, nitro, carbamoyl or C<sub>1-4</sub> alkanoylamino substituents; and~~

*Sub C2  
cont.*  
~~R<sup>7</sup> is a hydrogen atom or a C1-6 alkyl group.~~

10(original). Compounds of formula (I) as claimed in claim 9 wherein X represents a hydroxyl, amino, methylamino, ethylamino, -ethyl-N-methylamino, acetylamino, benzamido or phenylacetylarnino group.

*B1*  
11(previously presented). Compounds of formula (I) as claimed in claim 1 wherein Y contains up to 7 carbon atoms and up to 3 multiple bonds.

12(original). Compounds of formula (I) as claimed in claim 11 wherein Y is a straight chain C<sub>2-6</sub> group.

13(previously presented). Compounds of formula (I) as claimed in claim 1 wherein Y is substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group positioned  $\alpha$ -,  $\beta$ - or  $\gamma$ - to the group -C(R<sup>1</sup>)(R<sup>2</sup>), X or  $\alpha$ - to any triple bond present in the group Y.

14(original). Compounds as claimed in claim 11 wherein Y is selected from ethylene, trimethylene, tetramethylene, vinylene, buta-1,3-dienylene, prop-2-yneylene and 1-hydroxyprop-2-yneylene.

15(original). Compounds of formula (I) as claimed in claim 1 wherein:  
R<sup>1</sup> and R<sup>2</sup>, which may be the same or different, each represents a lower alkyl group;

Appl. No. 09/926,491  
Amendment dated: August 7, 2003  
Reply to OA of: April 7, 2003

$R^5$  represents a hydrogen atom; and  
 $X$  represents a group  $NR^6R^7$  wherein  $R^7$  is hydrogen.

16(original). The compounds:

*Sub C2 cont.*  
*B1*  
25-acetylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-ethylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-methylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-dimethylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-(N-ethyl-N-methylamino)-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-acetylamino-3-methoxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-acetylamino-3-ethoxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-acetylamino-3-isobutoxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-benzamido-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-phenylacetylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;

25-acetylamino-3-hydroxy-24-homo-19-nor-cholest-1,3,5(10)-triene;

3,24-dihydroxy-24-propargyl-19-26,27-trisnor-cholest-1,3,5(10)-triene;

2-methoxy-3,24-dihydroxy-24-propargyl-19,26,27-trisnor-cholesta-1,3,5(10)-triene;

3,24-dihydroxy-20-epi-24-propargyl-19,26,27-trisnor-cholest-1,3,5(10)-triene;

3,24-dihydroxy-24,24-bispropargyl-19-nor-chol-1,3,5(10),22-tetraene;

2-methoxy-3,24-dihydroxy-24,24-bispropargyl-19-nor-chol-1,3,5(10),22-tetraene;

3,24-dihydroxy-20-epi-24,24-bispropargyl-19-nor-chol-1,3,5(10),22-tetraene;

3-hydroxy-25-amino-26,27-bishomo-19-nor-cholest- 1,3,5(10)-trien-23-yne;

2-methoxy-3-hydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3-hydroxy-20-epi-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3-hydroxy-25-amino-26,27-bishomo-19-nor-cholest- 1,3,5(10)-triene;

Amendment dated: August 7, 2003

Reply to OA of: April 7, 2003

*Sub  
C2  
cont.*

2-methoxy-3-hydroxy-25-amino-26,27-bishomo-19-nor-cholesta-1,3,5(10)-triene;  
3-hydroxy-20-epi-25-amino-26,26-bishomo-19-nor-cholesta-1,3,5(10)-triene;  
3-hydroxy-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;  
2-methoxy-3-hydroxy-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

*B1*

3-hydroxy-20-epi-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;  
3,22-dihydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;  
2-methoxy-3,22-dihydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;  
3,22-dihydroxy-20-epi-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;  
2-methoxy-3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),16-tetraene;

2-methoxy-3-hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),16-tetraene;  
2-methoxy-3-hydroxy-25-acetylamino-19-nor-cholest-1,3,5(10),16-tetraene;  
2-methoxy-3-hydroxy-25-amino-19-nor-cholest-1,3,5(10),16-tetraene;  
3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),6,8,16-hexaene;  
3-hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),6,8,16-hexaene;  
3,25-dihydroxy-19-nor-cholest-1,3,5(10)-trien-23-yne;  
3,25-dihydroxy-19-nor-cholest-1,3,5(10)-triene;  
2-methoxy-3,25-dihydroxy-19-nor-cholest-1,3,5(10)-trien-23-yne;  
3,25-dihydroxy-20-epi-19-nor-cholest-1,3,5(10)-trien-23-yne;  
2-methoxy-3,25-dihydroxy-19-nor-cholest-1,3,5(10)-triene;  
3,25-dihydroxy-20-epi-19-nor-cholest-1,3,5(10)-triene;  
3,25-dihydroxy-24,24a-bishomo-19-nor-cholest-1,3,5(10),22,24(24a)-pentaene;  
25-amino-3-hydroxy-20-epi-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;  
25-acetylamino-3-hydroxy-20-epi-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;  
25-amino-3-hydroxy-20-epi-19-nor-cholest-1,3,5(10),16-tetraene;

Appl. No. 09/926,491  
Amendment dated: August 7, 2003  
Reply to OA of: April 7, 2003

~~25-acetylamino-3-hydroxy-20-epi-24-homo-19-nor-cholest-1,3,5(10),16-tetraene;  
3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),6,16-pentaene; and  
3-hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),6,16-pentaene.~~

*Sub  
C2  
com.  
B)*  
17(previously presented). Active compound of formula (I) as claimed in claim 1 for use in management of neoplastic disease; as agents to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia; in fertility control in either human or animal subjects; in management of disorders involving blood clotting; or in reduction of serum cholesterol.

Claim 18(canceled).

*Sub  
C2  
com.*  
~~19(previously presented). Pharmaceutical compositions comprising an active compound of formula (I) as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.~~

*Sub  
C2  
com.*  
20(previously presented). A method of treatment of a human or animal subject in the management of neoplastic disease; to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia; in fertility control; in management of disorders involving blood clotting; or in reduction of serum cholesterol, which method comprises administering to said subject

Appl. No. 09/926,491  
Amendment dated: August 7, 2003  
Reply to OA of: April 7, 2003

*Sub  
C2  
con*  
a therapeutically effective amount of an active compound of formula (I) as claimed in  
claim 1.

*B1*  
Claim 21(canceled).